Anti-Certolizumab Polyclonal Antibody|抗赛妥珠单抗多克隆抗体(靶标：赛妥珠单抗（抗TNF-α Fab'）)
- 货号：RB9TAF879054
- 价格：面议
- 点击：257
产品介绍
产品参数
| 形态 | Liquid |
|---|---|
| 宿主种属 | Rabbit |
| 克隆性 | Polyclonal |
| 抗体亚型 | IgG |
| 纯化方式 | Purified by antigen affinity column. |
| 内毒素水平 | Please contact with the lab for this information. |
| 应用 | ELISA |
| 特异性 | The product is specific for Certolizumab. This antibody serves as an excellent positive control for Certolizumab immunogenicity (ADA) assays. |
| 靶标 | Certolizumab |
| 免疫原 | Certolizumab |
| 储存缓冲液 | 0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300. |
| 稳定性和储存 | The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles. |
| 产品使用说明 | ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000 |
| 登录号 | CAS: 428863-50-7 |
| 背景信息 | Certolizumab is a Fab fragment of a monoclonal antibody to human tumor necrosis factor alpha (TNFα) which has potent antiinflammatory activity and is used in the therapy of severe rheumatoid arthritis and inflammatory bowel disease. Antibodysystem Anti-Certolizumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Certolizumab. • Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial., PMID:37423647 • Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis., PMID:32207094 • Certolizumab Pegol in Plaque Psoriasis: Considerations for Pregnancy., PMID:33769772 • Certolizumab treatment of localized pyoderma gangrenosum in a pregnant patient., PMID:37905433 • Certolizumab pegol for hidradenitis suppurativa: Case report and literature review., PMID:33135826 • Certolizumab pegol for induction of remission in Crohn's disease., PMID:31476018 • ACG Clinical Guideline: Management of Crohn's Disease in Adults., PMID:29610508 • [Certolizumab]., PMID:31208736 • Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation., PMID:27140438 • Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis., PMID:31917928 |
| 备注 | For research use only. |
相关产品: